Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Projections for the CAGR of the Glomerulonephritis Market Size From 2025 to 2034?

There has been a consistent increase in the glomerulonephritis market size over the past years. The market is projected to expand from $11.06 billion in 2024 to $11.61 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 4.9%. This upward trend during the historic period is largely due to the escalating occurrence of kidney diseases, the widespread presence of infections like post-streptococcal glomerulonephritis, advancements in research and development, a heightened number of kidney failure cases, and an increasing awareness of kidney-related ailments.

The market size of glomerulonephritis is projected for consistent expansion in the coming years, reaching$14.03 billion by 2029″ with a 4.9% compound annual growth rate (CAGR). This projected growth during the forecast period can be attributed to the rise in diabetes cases, an growing elderly population, increased healthcare expenditure, growth in the number of dialysis patients, and the surge in autoimmune diseases. The upcoming robust trends include the introduction of new treatments and therapies, evolving diagnostic technologies, innovative therapeutics, cooperative ventures between corporations, and the utilization of intravenous immunoglobulin therapy.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21193&type=smp

What Are the Core Market Drivers Propelling Growth in the Glomerulonephritis Industry?

The growth of the glomerulonephritis market is projected to be fuelled by the increasing occurrence of kidney disorders. This broad term encompasses various conditions impacting the kidneys’ structure or function, causing disrupted filtration, fluid balance, and waste elimination. The escalating incidence of kidney disorders is credited to elements such as growing older populations, elevated chronic disease rates like diabetes and hypertension, and lifestyle habits. These kidney disorders provoke glomerulonephritis by instigating immune system malfunctions, chronic inflammation, or structural harm, leading to decreased kidney filtration and functionality. For example, in December 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, reported that death rates from chronic kidney disease (CKD) rose by 4.2% in 2021 and 6.2% in 2022. In the years 2021-22, CKD was observed in roughly 2 million hospital admissions, making up 18% of all Australian hospital admissions. Therefore, the growing incidence of kidney disorders will spur the expansion of the glomerulonephritis market.

How Is the Glomerulonephritis Market Segmented?

The glomerulonephritismarket covered in this report is segmented –

1) By Type: Acute Glomerulonephritis; Chronic Glomerulonephritis

2) By Diagnosis: Urine And Blood Tests; Imaging Tests; Kidney Biopsy; Other Diagnosis

3) By Treatment: Medication; Surgery; Dialysis; Other Treatments

4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels

5) By End-User: Hospitals; Specialty Clinics; Other End-Users

Subsegments:

1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis; IgA Nephropathy; Lupus Nephritis; Rapidly Progressive Glomerulonephritis (RPGN); Goodpasture Syndrome

2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS); Membranous Nephropathy; Minimal Change Disease; Alport Syndrome; Diabetic Nephropathy; Hypertensive Nephrosclerosis

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21193&type=smp

Which Regions Are Driving the Next Phase of the Glomerulonephritis Market Growth?

North America was the largest region in the glomerulonephritis market in 2024. The regions covered in the glomerulonephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Glomerulonephritis Industry?

Leading firms in the glomerulonephritis market are concentrating on the development of innovative non-immunosuppressive treatments to meet unsatisfied health needs and enhance patient results. Non-immunosuppressive treatments refer to therapies that do not suppress or weaken the immune system, designed to manage disorders without hampering immune response. For example, in September 2024, Travere Therapeutics Inc., an American biopharmaceutical firm, launched FILSPARI (sparsentan), received approval from the FDA to treat IgA nephropathy, a kidney illness. The medicine is the only non-immunosuppressive treatment that demonstrated a significant reduction in kidney function deterioration in these patients. The approval of FILSPARI represents a significant advancement in treating IgA nephropathy, the most prevalent form of primary glomerulonephritis. This treatment provides a fresh alternative for patients who previously had limited options. This acceptance underscores Travere’s dedication to enhancing patient outcomes in cases of kidney disease.

View the full report here:

https://www.thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report

How Is the Glomerulonephritis Market Defined and What Are Its Core Parameters?

Glomerulonephritis is a kidney disorder characterized by inflammation of the glomeruli, the tiny filters in the kidneys that remove waste and excess fluids from the blood. It can result from infections, autoimmune diseases, or other underlying conditions, leading to symptoms such as blood in urine, proteinuria, and swelling. If left untreated, it may progress to chronic kidney disease or kidney failure.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21193

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model